DOCSLIB.ORG

Headline Is All Capitals In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Headline Is All Capitals In 2012 High-Cost Generic Tier 2 Drugs The listing below identifies select generic medications that are covered under the Tier 2 coinsurance level. Consult with your prescriber to identify which alternative medications are right for you. This listing is subject to change. Generics Covered Form Tier 1 Generic Alternative Under Tier 2 acetazolamide sustained action • acetazolamide tablet capsule acetic acid/ drops • aa/antpy/bcaine/polico/al acet drops • neomy sulf/polymyx b sulf/hc suspension drops hydrocortisone • acetic acid/aluminum acetate drops • ofloxacin drops • antipyrine/benzocaine/glycerin drops • hc/pramoxine hcl/chloroxylenol drops alprazolam sustained release 24hr • alprazolam tablet • diazepam solution oral tablet • buspirone tablet • lorazepam tablet • chlordiazepoxide capsule • lorazepam concentrate oral rapid dissolve tablet • clorazepate tablet • oxazepam capsule • diazepam tablet amlodipine- tablet • amlodipine + simvastatin • amlodipine + lovastatin atorvastatin • amlodipine + pravastatin amphet asp/amphet/ sustained release 24 • amphet asp/amphet/d-amphet • dextroamphetamine tablet d-amphet hr capsule (amphetamine salt combo) immediate release tablet • dextroamphetamine capsule sustained action apraclonidine hcl drops • brimonidine drops • levobunolol drops • dorzolamide drops • timolol maleate gel-forming solution • dorzolamide/timolol drops • timolol maleate drops • latanoprost drops atorvastatin calcium tablet • simvastatin tablet • lovastatin tablet • pravastatin tablet Generics Covered Form Tier 1 Generic Alternative Under Tier 2 azelastine hcl drops • ketorolac drops betamethasone gel • alclometasone cream • fluocinolone cream dipropionate • alclometasone ointment • fluocinolone ointment • amcinonide cream • fluticasone ointment • amcinonide ointment • fluticasone cream • amcinonide lotion • halobetasol ointment • betamethasone cream • halobetasol cream • betamethasone ointment • hydrocortisone cream • betamethasone lotion • hydrocortisone ointment • clobetasol ointment • hydrocortisone lotion • clobetasol ream • hydrocortisone solution non-oral • clobetasol solution non-oral • mometasone cream • clobetasol gel • mometasone ointment • desonide cream • mometasone solution non-oral • desonide lotion • prednicarbate cream • desonide ointment • triamcinolone cream • desoximetasone cream • triamcinolone ointment • diflorasone ointment • triamcinolone lotion • fluocinolone solution • triamcinolone cream bromfenac sodium drops • diclofenac drops • ketorolac drops budesonide delayed & extended • dexamethasone tablet • methylprednisolone tablet release capsule • dexamethasone elixir • prednisolone solution oral • dexamethasone solution oral • prednisone tablet • hydrocortisone tablet clindamycin foam • clindamycin lotion • clindamycin solution non-oral phosphate • clindamycin gel • clindamycin swab medicated Generics Covered Form Tier 1 Generic Alternative Under Tier 2 clobetasol propionate foam • alclometasone cream • fluocinolone cream • alclometasone ointment • fluocinolone ointment • amcinonide cream • fluticasone ointment • amcinonide ointment • fluticasone cream • amcinonide lotion • halobetasol ointment • betamethasone cream • halobetasol cream • betamethasone ointment • hydrocortisone cream • betamethasone lotion • hydrocortisone ointment • clobetasol ointment • hydrocortisone lotion • clobetasol ream • hydrocortisone solution non-oral • clobetasol solution non-oral • mometasone cream • clobetasol gel • mometasone ointment • desonide cream • mometasone solution non-oral • desonide lotion • prednicarbate cream • desonide ointment • triamcinolone cream • desoximetasone cream • triamcinolone ointment • diflorasone ointment • triamcinolone lotion • fluocinolone solution • triamcinolone cream clonidine transdermal weekly • clonidine tablet patch cyclobenzaprine hcl sustained release 24 • baclofen tablet • dantrolene capsule hr capsule • carisoprodol tablet • methocarbamol tablet • carisoprodol/aspirin tablet • methocarbamol tablet • chlorzoxazone tablet • orphenadrine tablet sustained action • cyclobenzaprine immediate release tablet • tizanidine tablet desipramine hcl tablet • amitriptyline tablet • doxepin capsule • amoxapine tablet • imipramine tablet • clomipramine capsule • maprotiline tablet • doxepin capsule • nortriptyline capsule • doxepin concentrate oral Generics Covered Form Tier 1 Generic Alternative Under Tier 2 desoximetasone gel • alclometasone cream • fluocinolone cream • alclometasone ointment • fluocinolone ointment ointment • amcinonide cream • fluticasone ointment • amcinonide ointment • fluticasone cream • amcinonide lotion • halobetasol ointment • betamethasone cream • halobetasol cream • betamethasone ointment • hydrocortisone cream • betamethasone lotion • hydrocortisone ointment • clobetasol ointment • hydrocortisone lotion • clobetasol ream • hydrocortisone solution non-oral • clobetasol solution non-oral • mometasone cream • clobetasol gel • mometasone ointment • desonide cream • mometasone solution non-oral • desonide lotion • prednicarbate cream • desonide ointment • triamcinolone cream • desoximetasone cream • triamcinolone ointment • diflorasone ointment • triamcinolone lotion • fluocinolone solution • triamcinolone cream dextroamphetamine sustained action • amphet asp/amphet/d-amphet • dextroamphetamine tablet sulfate capsule (amphetamine salt combo) tablet Generics Covered Form Tier 1 Generic Alternative Under Tier 2 diflorasone diacetate cream • alclometasone cream • fluocinolone cream • alclometasone ointment • fluocinolone ointment • amcinonide cream • fluticasone ointment • amcinonide ointment • fluticasone cream • amcinonide lotion • halobetasol ointment • betamethasone cream • halobetasol cream • betamethasone ointment • hydrocortisone cream • betamethasone lotion • hydrocortisone ointment • clobetasol ointment • hydrocortisone lotion • clobetasol ream • hydrocortisone solution non-oral • clobetasol solution non-oral • mometasone cream • clobetasol gel • mometasone ointment • desonide cream • mometasone solution non-oral • desonide lotion • prednicarbate cream • desonide ointment • triamcinolone cream • desoximetasone cream • triamcinolone ointment • diflorasone ointment • triamcinolone lotion • fluocinolone solution • triamcinolone cream dihydroergotamine ampule • ergotamine tartrate/caffeine tablet • naratriptan tablet mesylate • isomethept/acetaminop/dichlphn capsule • sumatriptan spray non-aerosol • sumatriptan tablet diltiazem hcl (Matzim sustained release 24hr • amlodipine tablet • isradipine capsule LA™) tablet • diltiazem capsule degradable controlled- • nicardipine capsule release • nifedipine tablet sustained action • diltiazem capsule sustained release 24 hr • nifedipine tablet extended release 24 hr • diltiazem capsule sustained release 12 hr • nifedipine capsule • diltiazem capsule sustained action • verapamil tablet sustained action • diltiazem tablet • verapamil capsule 24hr sustained release pellets • felodipine tablet sustained release 24hr • verapamil tablet dronabinol capsule • ondansetron tablet • prochlorperazine tablet • ondansetron solution • promethazine suppository • prochlorperazine suppository • promethazine hcl tablet epinastine hcl drops • ketorolac drops Generics Covered Form Tier 1 Generic Alternative Under Tier 2 eplerenone tablet • amiloride tablet • spironolactone tablet eprosartan tablet • losartan famotidine oral suspension • cimetidine solution oral • ranitidine syrup • nizatidine solution oral fentanyl citrate lozenge • morphine solution oral (solution) • oxycodone tablet • morphine tablet • oxycodone capsule flavoxate hcl tablet • oxybutynin tablet • oxybutynin extended release 24 hr • oxybutynin syrup hydroxyzine hcl vial • hydroxyzine tablet • promethazine vial • hydroxyzine syrup • promethazine ampul • hydroxyzine capsule • promethazine syrup • promethazine tablet imipramine pamoate capsule • amitriptyline tablet • doxepin capsule • amoxapine tablet • imipramine tablet • clomipramine capsule • maprotiline tablet • doxepin capsule • nortriptyline capsule • doxepin concentrate oral Sotret™ capsule • adapalene gel • tretinoin gel Claravis™, • adapalene cream • tretinoin cream Amnesteem™ (active • tretinoin cream ingredient: isotretinoin) levofloxacin drops • ciprofloxacin drops • ofloxacin drops • gentamicin drops • polymyxin b sulfate/tmp drops • gentamicin drops • tobramycin sulfate drops • neomycin/polymyxn b/gramicidin drops lindane lotion • permethrin cream Generics Covered Form Tier 1 Generic Alternative Under Tier 2 malathion lotion • permethrin cream meclofenamate capsule • diclofenac tablet • etodolac tablet sustained release 24hr sodium • diclofenac tablet sustained release 24hr • fenoprofen tablet • diclofenac tablet delayed release • flurbiprofen tablet • etodolac capsule • ibuprofen tablet • etodolac tablet • indomethacin capsule mefenamic acid capsule • diclofenac tablet • etodolac tablet sustained release 24hr • diclofenac tablet sustained release 24hr • fenoprofen tablet • diclofenac tablet delayed release • flurbiprofen tablet • etodolac capsule • ibuprofen tablet • etodolac tablet • indomethacin capsule meprobamate tablet • alprazolam tablet • diazepam solution oral • buspirone tablet • lorazepam tablet • chlordiazepoxide capsule • lorazepam concentrate oral • clorazepate tablet • oxazepam capsule • diazepam tablet mesalamine kit • mesalamine enema (not kit) w/cleansing wipes metaxalone tablet • baclofen tablet • dantrolene capsule • carisoprodol tablet • methocarbamol tablet • carisoprodol/aspirin tablet
Load more

Recommended publications
  • Softgels' Clear Advantages
    DEEPDIVE REPORT March 2019 naturalproductsinsider.com Softgels’ Clear Advantages Report brought to you by DEEPDIVE REPORT Softgels’ Clear Advantages Contents Market snapshot ..................................................................................... 3 Consumer appeal .................................................................................... 4 Softgel history .......................................................................................... 6 Advantages of softgels ........................................................................... 7 How softgels are made .......................................................................... 9 Softgel challenges and solutions .......................................................11 Oxidation ...........................................................................................11 Consumer experience .......................................................................12 Dietary considerations ......................................................................12 Shelf stability ....................................................................................14 Bioavailability ....................................................................................14 Innovative developments .....................................................................16 Copyright © 2019 Informa Exhibitions LLC. All rights reserved. The publisher reserves the right to accept or reject any advertising or editorial material. Advertisers, and/or their agents, assume the
    [Show full text]
  • Oral Drug Delivery: Formulation Selection Methods & Novel Delivery Technologies
    ORAL DRUG DELIVERY: FORMULATION SELECTION METHODS & NOVEL DELIVERY TECHNOLOGIES OUTSTANDING ISSUE SPONSOR www.ondrugdelivery.com “Oral Drug Delivery: Formulation Selection Approaches CONTENTS & Novel Delivery Technologies” This edition is one in the ONdrugDelivery series of pub- No Longer a Hit-or-Miss Proposition: lications from Frederick Furness Publishing. Each issue focuses on a specific topic within the field of drug deliv- Once-Daily Formulation for Drugs with ery, and is supported by industry leaders in that field. pH-Dependent Solubility Gopi Venkatesh, Director of R&D & Anthony Recupero, EDITORIAL CALENDAR 2011: Senior Director, Business Development June: Injectable Drug Delivery (Devices Focus) Aptalis Pharmaceutical Technologies 4-8 July: Injectable Drug Delivery (Formulations Focus) September: Prefilled Syringes A possible approach for the desire to innovate October: Oral Drug Delivery Brian Wang, CEO & Dr Junsang Park, CSO November: Pulmonary & Nasal Drug Delivery (OINDP) GL PharmTech 10-13 December: Delivering Biotherapeutics SUBSCRIPTIONS: COMPANY PROFILE - To arrange your FREE subscription (pdf or print) to Mayne Pharma International 14-15 ONdrugDelivery, contact: Guy Furness, Publisher From Powder to Pill: A Rational Approach to T: +44 (0) 1273 78 24 24 E: [email protected] Formulating for First-into-Man Studies Dr Robert Harris, Director, Early Development SPONSORSHIP/ADVERTISING: Molecular Profiles Ltd 16-19 To feature your company in ONdrugDelivery, contact: Guy Furness, Publisher LiquiTime* Oral Liquid
    [Show full text]
  • Oral Dosage Forms That Should Not Be Crushed Formulary-Specific List for VCMC and SPH
    Oral Dosage Forms That Should Not be Crushed Formulary-Specific List for VCMC and SPH Generic Brand Dosage Form(s) Reasons/Comments amoxicillin-clavulanate Augmentin XR Tablet Slow-release (b,h) aspirin Aspirin EC Caplet; Tablet Slow-release; Enteric-coated aspirin and dipyridamole Aggrenox XR Capsule Slow-release atazanavir Reyataz Capsule Note: an oral powder is available, see prescribing information for administration instructions atomoxetine Strattera Capsule Note: capsule contents can cause ocular irritation - Do not open capsules as contents are an ocular irritant benzonatate Tessalon Perles Capsule Note: swallow whole; local anesthesia of the oral mucosa; choking could occur - Capsules are liquid-filled “perles” - Do not alter (break, cut, chew) integrity of dosage form; local mucosal irritant and anesthetic bisacodyl Dulcolax Capsule; Tablet Enteric-coated (c) bosentan Tracleer Tablet Note: women who are, or may become, pregnant, should not handle crushed or broken tablets brivaracetam Briviact Tablet Film-coated (b) budesonide Entocort EC Capsule Enteric-coated (a) - Capsules contain enteric-coated granules in extended-release matrix; can open capsules but do not crush contents - Products are formulated to release active drug at mid- to late small intestine buPROPion Wellbutrin XL Tablet Slow-release - Do not crush extended-release tablets - Immediate-release tablet products may be film-coated March 2019 carvedilol phosphate Coreg CR Capsule Slow-release (a) (Note: may add contents of capsule to chilled, not warm, applesauce
    [Show full text]
  • DESONATE® (Desonide) Gel 0.05% for Topical Use Only • Systemic Absorption May Require Evaluation for HPA Axis Suppression Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------- WARNINGS AND PRECAUTIONS------------------------ These highlights do not include all the information needed to use • Topical corticosteroids can produce reversible hypothalamic pituitary DESONATE Gel safely and effectively. See full prescribing information adrenal (HPA) axis suppression, Cushing's syndrome and unmask latent for DESONATE Gel. diabetes. (5.1) DESONATE® (desonide) Gel 0.05% for topical use only • Systemic absorption may require evaluation for HPA axis suppression Initial U.S. Approval: 1972 (5.1). • Modify use should HPA axis suppression develop (5.1) ---------------------------- INDICATIONS AND USAGE--------------------------- • Potent corticosteroids, use on large areas, prolonged use or occlusive use may increase systemic absorption (5.1) DESONATE is a corticosteroid indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. (1) • Local adverse reactions may include atrophy, striae, irritation, acneiform eruptions, hypopigmentation, and allergic contact dermatitis and may be ---------------------- DOSAGE AND ADMINISTRATION----------------------- more likely with occlusive use or more potent corticosteroids. (5.2, 5.4, 6) • Apply as a thin layer to the affected areas two times daily and rub in • Children may be more susceptible to systemic toxicity when treated with gently. (2) topical corticosteroids. (5.1, 8.4) • Therapy should be discontinued when control is achieved. (2) • If no improvement is seen within 4 weeks, reassessment of diagnosis ------------------------------ ADVERSE REACTIONS------------------------------- may be necessary. (2) The most common adverse reactions (incidence ≥ 1%) are headache and • Should not be used with occlusive dressings. (2) application site burning. (6) • Treatment beyond 4 consecutive weeks is not recommended. (2) To report SUSPECTED ADVERSE REACTIONS, contact LEO Pharma • For topical use only.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • A Randomized and Observer Blinded Comparison of Continuous Femoral
    a & hesi C st lin e ic n a l A f R Möller. J Anesthe Clinic Res 2011, 4:1 o e l s e a Journal of Anesthesia & Clinical DOI: 10.4172/2155-6148.1000.277 a n r r c u h o J ISSN: 2155-6148 Research Case Report Open Access A Randomized and Observer Blinded Comparison of Continuous Femoral Block and Fascia Iliaca Compartment Block in Hip Replacement Surgery Thorsten Möller1,2, Sabine Benthaus2, Maria Huber2, Ingrid Bentrup2, Markus Schofer3, Leopold Eberhart2, Hinnerk Wulf2 and Astrid Morin2* 1Department of Anesthesiology and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany 2Department of Anesthesiology and Critical Care Medicine, Philipps-University Marburg, Marburg, Germany 3Department of Orthopedy and Rheumatology, Philipps-University Marburg, Marburg, Germany Abstract Background: Techniques, analgesic effects and functional outcome of continuous femoral nerve and fascia iliaca compartment blocks were compared in patients undergoing hip replacement surgery. Methods: 80 patients were enroled in this randomized and observer-blinded study. 40 patients received a femoral nerve catheter with a stimulating catheter (FEM group) and 40 patients a fascia iliaca compartment catheter (FIC group). Before surgery, the catheters were placed. 50 mL prilocaine 1% was administered and a continuous infusion of ropivacaine 0.2% was maintained for 24 hours. Postoperative pain management with non-steroidal anti- inflammatory agents was standardized during the first 24 hours. No bolus application of a local anesthetic was allowed during this period. Intravenous opioide PCA with piritramide (comparable with morphin) was provided for 24 hours, and the patients were instructed to titrate their pain below a level of visual analogue scale of 3.
    [Show full text]
  • Steroids Topical
    Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
    [Show full text]
  • Continuous Pericapsular Nerve Group Block for Postoperative Pain
    Fujino et al. JA Clinical Reports (2021) 7:22 https://doi.org/10.1186/s40981-021-00423-1 CASE REPORT Open Access Continuous pericapsular nerve group block for postoperative pain management in total hip arthroplasty: report of two cases Takashi Fujino1* , Masahiko Odo1, Hisako Okada1, Shinji Takahashi2 and Toshihiro Kikuchi1 Abstract Background: Total hip arthroplasty (THA) is one of the surgical procedures associated with severe postoperative pain. Appropriate postoperative pain management is effective for promoting early ambulation and reducing the length of hospital stay. Effects of conventional pain management strategies, such as femoral nerve block and fascia iliaca block, are inadequate in some cases. Case presentation: THA was planned for 2 patients with osteoarthritis. In addition to general anesthesia, continuous pericapsular nerve group (PENG) block and lateral femoral cutaneous nerve (LFCN) block were performed for postoperative pain management. Numerical rating scale (NRS) scores measured at rest and upon movement were low at 2, 12, 24, and 48 h postoperatively, suggesting that the treatments were effective for managing postoperative pain. The Bromage score at postoperative days (POD) 1 and 2 was 0. Conclusion: Continuous PENG block and LFCN block were effective for postoperative pain management in patients who underwent THA. PENG block did not cause postoperative motor blockade. Keywords: Pericapsular nerve group (PENG) block, Continuous peripheral nerve block, Total hip arthroplasty, Peripheral nerve block Background reported that it was more effective for managing postop- Total hip arthroplasty (THA) is associated with signifi- erative pain associated with THA than conventional cant postoperative pain [1]. Opioids are typically used peripheral nerve blocks [6].
    [Show full text]
  • Medication List
    Medication List Walgreens Plus™ members receive discounts on thousands of generic and brand-name medications included on this Medication List, which is divided into two sections, “Value Priced” Medications and “Discounted” Medications*. The price for a medication identified as “Value-Priced” is listed below: Get savings up to 85% off Cash Prices • 30-day-supply drugs cost $5 (tier 1), $10 (tier 2) or $15 (tier 3) on Atorvastatin (generic Lipitor) and • 90-day-supply drugs cost $10 (tier 1), $20 (tier 2) or $30 (tier 3) Rosuvastatin (generic Crestor) †† The Discounted Medications section lists the discounts offered to Walgreens Plus members on other generic and brand-name medications not included in the Value-Priced Medication section. The price for a medication is based on its tier and whether it is a 30-day or 90-day supply†. There may be an additional cost for quanities greater than those listed. This discount prescription pricing applies only to Walgreen Plus members on prescriptions purchased in select Walgreens stores that are not billed to insurance and/or used in combination with other health or pharmacy benefit programs. For further details, see your pharmacist or Walgreens.com/Plus. VALUE GENERICS NAPROXEN 250MG TAB 2 60 180 Antifungal NAPROXEN 500MG TAB 2 60 180 Quantity NAPROXEN 375MG TAB 2 60 180 Drug Name Tier 30 90 NAPROXEN DR 500MG TAB 3 60 180 FLUCONAZOLE 150MG TAB 2 1 3 TERBINAFINE 250MG TAB 2 30 90 Asthma Quantity Antiviral Drug Name Tier 30 90 Quantity ALBUTEROL 0.083% INH SOLN 25X3ML 2 75 225 Drug Name Tier 30 90 AMINOPHYLLINE
    [Show full text]
  • Capsule Robot: a Theranostic Approach
    Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) Volume 3 Issue 10 October 2019 Review Article Capsule Robot: A Theranostic Approach Pradnya Palekar Shanbhag*, Tejal Gawade, Prerna Patil and Priyanka Deshmukh Department of Pharmaceutics, Oriental College of Pharmacy, Sanpada, Navi Mumbai, Affiliated to University of Mumbai, India *Corresponding Author: Pradnya Palekar Shanbhag, Head and Professor, Department of Pharmaceutics, Oriental College of Pharmacy, Sanpada,Received: Navi September Mumbai, 11, Affiliated 2019 ; Published: to University September of Mumbai, 27, India. 2019 DOI: 10.31080/ASPS.2019.03.0407 Abstract Increasing development in healthcare systems and availability of efficient miniaturized components or systems that are economic has led to profound scope for research in many new fields. Capsule robot was one such fictional idea that turned into factual reality because of use of applicative miniaturized components. Initially capsule robots were developed for endoscopic applications. These travel inside the gastrointestinal tract and thus capture images of the gastrointestinal tract and related areas. Later, capsule robots were developed to be used as the unique tool to construct micron and sub-micron sized drug delivery systems for target delivery and treatment. This article highlights on various aspects of capsule robots in diagnosis and therapy of various disorders and diseases, togetherKeywords: called Capsule theranostic Robot; approachEndoscopy; in Diagnosis;drug delivery Therapy systems. Introduction The rising demand for non invasive methodology for diagnosis controlled manner, Drug Delivery System (DDS) capsule endoscopy was designed. There are quite a number of research studies using rine type capsules which travel inside the body were used for en Microelectromechanical Systems (MEMS) for evaluating the drug and treatment led to the invention of capsule robots.
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • Medical Review~ Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 21-978 MEDICAL REVIEW~ CLINICAL REVIEW Application Type NDA Submission Number 21-978 Submission Code 000 Letter Date November 18, 2005 Stamp Date November 28, 2005 PDUFA Goal Date September 21,2006 Reviewer Name Denise Cook, M.D. Review Completion Date 8/28/06 Established Name Desonide (Proposed) Trade Name .. Therapeutic Class Topical corticosteroid Applicant Connectics Priority Designatiop S Formulation Foam, 0.05% Dosing Regimen bid Indication F or the treatment of mild to moderate atopic dermatitis . Intended Population Age 3 months and above Clinical Review Denise Cook, M.D. NDA 21-978/ N-OOO _ loam, 0.05%/desonide foam, 0.05% Table of Contents 1 EXECUTIVE SUMMARy................................................................................................................................5 1.1 RECOMMENDATION ON REGULATORY ACTION ...........................................................................................5 1 .2 RECOMMENDATION ON POSTMARKETING ACTIONS. .............. ...... .... .... ........... ........ ..... ... ..... ...... ......... ........5 1.2. I Risk Management Activity................ ......... ..... ............... ..... ................... ........ ........ .... ....... ... ......... ........5 1.2.2 Required Phase 4 Commitments............................................................................................................5 1.2.3 Other Phase 4 Requests..........................................................................................................................5
    [Show full text]